

October 1997 Issue | Mitchell Kaminski, M.D.

<http://jeffreybland.com/knowledgebase/october-1997-issue-mitchell-kaminski-m-d/>

[DOWNLOAD AUDIO](#) |

Welcome to *Functional Medicine Update* for October 1997. This month we will focus on gastrointestinal and hepatic interrelationships and disorders of inflammatory liver disease, inflammatory bowel disease, and their relationship to systemic inflammation.

I would like to begin with a topic that has been in the news lately, the diet controversy related to low-fat, high complex carbohydrate diet versus the higher-protein, lower-carbohydrate diet, and their relationship to weight management. We are in an interesting period in medical technology, when people are looking for the best drug to treat obesity.

The approval by the FDA of the drug Redux, a dexfenfluramine compound for weight loss and weight management in the morbidly obese individual, has led to an industry of drug-facilitated weight loss for people who are not morbidly obese and are looking for cosmetic weight loss. Advertisements feature doctors administering the "fen-phen" program and its promotion of weight loss and improved body cosmetics. This new industry has made billions of dollars through this medication approach to weight loss.

The use of pills and appetite-suppressant drugs for weight loss is nothing new. Stimulant drugs and epinephrine-like compounds have been around for some time. People apparently believe these serotonin-mimetic compounds, which cut carbohydrate craving and somehow control appetite, are safer and more effective than the previous stimulant drugs for weight loss. For this reason people have overlooked the more complicated questions regarding which diets, nutritional programs, and lifestyle modification programs are best for not only losing weight, but also for maintaining long-term improved body composition

It is time to put into perspective what we have learned, as of October 1997, about these medication-facilitated weight-loss programs. The *New England Journal of Medicine*(1997;337:629) recently published a powerful editorial describing concerns about these approaches. It reports that between 1967 and 1972, there was a serious outbreak of primary pulmonary hypertension in Western Europe. The incidence of this disorder among patients seen in major cardiac catheterization centers in Switzerland, Germany, and Austria increased by a factor of 10.

This unusual epidemic could be traced to the use of an appetite-suppressant drug called aminorex (Menocil), which was introduced in Europe for weight loss shortly before the epidemic was observed. The drug was quickly withdrawn from the market, which was a good thing, because morbidity and mortality among people taking this drug was about 50 percent higher than those who were not. In fatal

cases, postmortem examinations revealed obstruction lesions in the muscular pulmonary arteries, which is not a benign condition.

We often have short memories. The lesson learned from the adverse effects of anorectic drugs gradually faded. Three decades later, in the early 1990s, another outbreak of primary pulmonary hypertension in Europe was linked to dexfenfluramine (Redux) and fenfluramine (Pondimin). The risk of developing pulmonary hypertension was 2300 percent higher among patients who used these drugs for more than three months, compared to untreated control patients. One could say that even at 23 times higher, this is still a very small absolute number of patients who experienced primary pulmonary hypertension as a secondary effect of using these medications. Recently, however, the *New England Journal of Medicine* (1997;337:602) and several other primary medical journals have featured reports about adverse effects of these drugs beyond primary pulmonary hypertension.

INTERVIEW TRANSCRIPT

Mitchell Kaminski, M.D., F.A.C.S., F.I.C.S., F.A.C.N.
Thorek Hospital & Medical Center,
850 West Irving Park Road
Chicago, IL 60613-3098
Phone: (773) 975-6726 FAX (773)975-6741

We are fortunate to have as our Clinician of the Month a man whom I professionally and personally admire for his insight, dedication, and clinical acumen, who brings us some insights into the gastrointestinal/hepatic connection to chronic illness and how it can be a useful entry point for nutritional therapy for a variety of problems related to inflammation, atopy, allergy, and degenerative disease risk. Dr. Mitchell Kaminski is certified both as a surgeon in internal medicine, and in nutrition. He is a clinical professor of surgery at the Finch University of Health Sciences, Chicago Medical School. He works at Thorek Hospital outside of Chicago and has a very active practice. Dr. Kaminski combines the inquiring mind of a researcher with that of an astute clinician, and he balances those two worlds very well. On the one hand, he explores the frontiers of new information, and on the other he sieves that information and delivers it in effective ways to patients so they can benefit from what is both new and reasonable.

JB: Dr. Kaminski, it is a pleasure to have you on *Functional Medicine Update*. What drew you into nutrition from your background in surgery and internal medicine?

MK: Thank you, Jeff. It's a pleasure to be here. Although I've been accused of being an internist, people forget that I am a board-certified surgeon and that I also have my Boards in nutrition. I am not a trained internal medicine fellow, although in the way things function, looking at the patient holistically, there has to be a lot of medicine practiced on the part of any surgeon.

I got into the nutrition area by a series of accidents. I took my residency at Walter Reed during the Viet Nam conflict, with every intention of becoming a plastic surgeon, but I became impressed with a very new technique. In fact, I was involved in the care of the first patient in the department of surgery that eliminated malnutrition from disease and trauma. That technique is called intravenous hyperalimentation,

or TPN.

As time went on, it became evident that the gastrointestinal tract is God's way to feed and that if you have a patient who cannot eat, but has a gut that works, it was wiser, just intuitively, to use the intestine to deliver the nutrients via a tube being placed either nasogastrically or by other surgical means. And that's how we got into it.

When we eliminated malnutrition from disease and trauma, none of the young men who came to us with severe war wounds who were expected to die did so. We applied that technology to people with other very serious conditions that were potentially reversible or treatable. When we eliminated malnutrition from that algorithm, they didn't die, although they had been expected to die. One thing led to another, and I set aside the idea of becoming a plastic surgeon and devoted my time to understanding the link between nutritional support and outcome. It's been a lot of fun. It's led me down the yellow brick road; I'm still clicking my heels and enjoying every minute of it.

JB: One way you have really assisted me and countless others who have been fortunate enough to be associated with you or listen to your lectures, is in the way you have developed the concepts of gut function, immunological function, and the inflammatory cascade. From a clinical perspective, how do you see the gut and the immune system as being interrelated, and how do you communicate that relationship to patients and put together treatment programs based on that model?

MK: My earliest appreciation for the interlink of the immune function of the gut also stems back to my Army days. I spent nine years in the Army. The last year I was assistant chief of the Physical Sciences Division out at Fort Dietrick and our job there was biological war defense. A coworker had discovered small molecules released by monocytes that had hormone-like effects, apocrine-like effects, and paracrine-like effects.

At the time we called it LEM -- leukocyte endogenous mediator. Today they are called cytokines. The link to the intestine became heightened when, using my interest in feeding the gut, I began to contribute to the literature that clearly showed that if you did not use the gut, you had problems systemically and globally with decreased immune function and the appearance of deep sepsis in organs remote to the intestine. When you did use the gut, even at a very minimal rate, you maintained immunity globally.

That science has progressed quite a bit now, and it has proved to be absolutely true. Looking at it in a more focused way with the HIV problem, doing reading around that, employing the background knowledge and then updated knowledge of cytokines, it became apparent that the gut is the center of the immune system. In fact, there are more immune cell elements in the intestine than in the bone marrow, liver, spleen, and Kupffer cells combined. It is a very exciting and very dramatic center of your immune system.

JB: You are now referring to what has been abbreviated in the literature as the GALT, the gut associated lymphoid tissue, how that is modulated, how it relates to dendritic cell activity and mucosal cell activities. That is becoming a fascinating story. Some of those messenger substances are even interconnected with brain neurohormones. It is hard now to partition our physiology into specific subcategories. Using this model, it appears to me that as a surgeon you are addressing the patient as an interconnected whole being rather than just dealing with organ parts as isolated pathology events.

MK: Absolutely. Dr. Leo Galland, one of your previous contributors, enlightened me to the fact that there is not a single neurotransmitter or receptor in the brain that you do not also find in the intestine. Even more important is the area you and your group have so eminently contributed to, namely dysbiosis. Dysbiosis leading to adhesion of pathogenic organisms to the mucosa, causing inflammation and leaky gut, is real. I am very fond of testing that. I have found a link between dysbiosis and the exacerbation, or worsening, of virtually any other condition the patient has, from AIDS to arthritis. This is something that you and your group have put out over and over again, and it is slowly working its way into the allopathic thinking. The contribution of Great Smokies Diagnostic Laboratory, in giving us the tools to objectively measure it, to correct it, and objectively measure it again is beautiful. That's the allopathic system. Now we can bring all of this wonderful nutrition into this arena.

JB: It seems the body is triggered by a balance of effector molecules, activators, and inhibitors. When we look specifically at the inflammatory markers, the so-called TH1 and TH2 system, how do you see the relationship of the gut to the cytokines of the proinflammatory and anti-inflammatory systems?

MK: T-helper cells can be in different states of activation. First, they may be in a TH zero, or a resting state, in which they put out a little gamisch of cytokines and are not particularly oriented in one direction or another. Second, they may be stimulated to a lower state of readiness. The TH1, or some people might even call those the anti-inflammatory or idling up-stage set, produce predominantly interleukin 2 and INF gamma. That is the state of readiness in which most of us find ourselves now.

If there is a persistent antigen load, however, whether it is an infection, inflammation, radiation, or a state of gut dysbiosis or leaky gut, with organic molecules and other protein peptides coming across, constantly bombarding this set with other cytokines, the T-helper cells switch into what you might call a pro-inflammatory state. It is as though they say, "I've got to find the invader. I've got to mobilize myself and destroy this invader." That state is characterized by IL 4,5,6,8,10, tumor necrosis factor alpha and so on. That kind of a cytokine set gives you, in effect, a chronic state of subclinical endotoxemia. People in this condition are, as you have fondly pointed out, our "walking wounded." You can find that walking-wounded set linking back to what I said earlier as part of the pathology. This makes conditions, which should respond to treatment, very difficult to treat.

I would like to use one example. A good friend and colleague of mine, Dr. Raja Atiyah, is a well-known head and neck cosmetic surgeon who is a big name in allergy. He and I have been collaborating on several small projects. He found a paper describing research on resistant-to-treatment, chronic allergic sinusitis in patients who had a nose job, sub-mucous resection, to correct a cosmetic defect. The study looked at the mucosa there for free radical scavengers like glutathione, uric acid, vitamin C, vitamin E, and so on. They found they had adequate tissues.

Then the tissues of people who were not responding to any form of treatment in the allopathic system were biopsied and found to be deficient in free radical scavengers. So, on his own, without asking me, Dr. Atiyah went ahead and loaded up his patients with vitamin A, vitamin C, glutathione, selenium, and CoQ10. He has had 27 patients now, all in a row, about whom, in his own words, he has said, "They're not improved, Mitch; they're cured!" That antioxidant link to the TH1/TH2 profiles is clear in regard to the perpetuation of the chronic illness. Free radicals are produced which then stimulate NF-*Kappa* B, I-*Kappa* B to separate. The NF-*Kappa* B goes to the nucleus, tells the nucleus to make more TH2 cytokines, which then produce more free radicals, and unless you intervene with a nutritional therapy to

stop that link, you are going to have this ongoing problem.

JB: That is a beautiful segue into very exciting work you have been doing as a pioneer in the area of HIV/AIDS, looking at that, again, as an inflammatory and noninflammatory-modulated immunological problem and how it relates to the gut. Could you tell us how you are approaching that?

MK: That is, in fact, how I came to know you. I was the national medical director of a company that was interested in HIV. I took it upon myself to do a little reading, and I discovered several papers that clearly said HIV is a TNF (tumor necrosis factor) disease. TNF is the signal to the virus genome to begin replication.

I said, "well, fine. Where does TNF come from?" Let's just not have any TNF around. And TNF, of course, is the principal inflammatory mediator. It kicks off the other mediators, making you ill, anorexia prostration and the whole TH2 cytokine set, and so on.

People normally do not have this inflammation going on. So where is it going to come from? You have episodic surges of TNF when you get a cold. Or if you eat a bad bug, and you have a little period of diarrhea. But those can be controlled. Where does the TNF chronically come from?

Once again, you look at the intestine. We have ambulatory people with dysbiosis who are putting out the inflammatory mediator tumor necrosis factor (and, by the way, there are several others). It goes to the cell and, as we mentioned, it's not actually TNF that tells the genome of the virus to replicate. It's free nuclear factor *Kappa B*. So NF-*Kappa B* not only kicks off the cytokine set to make you ill, but NF-*Kappa B* also tells the genome of the virus to replicate most efficiently. Obviously, the next strategy would be to do things to preserve the intestine and maintain the strength of the intestine as the focus of the immune system.

How it links to you is that, I had learned this, and I wrote a paper called "The gut hypothesis," about HIV. A representative from an organization with which you are familiar walked into my office, and I thought I would challenge his mind. Well, he knew everything I knew; and he knew things I wanted to know. Then he told me about you and your work several years ago, now, and you really are my teacher in this.

It became apparent that you have to defend against episodic surges of TNF. You have to repair any dysbiosis. Then you have to take a look, as we mentioned, at the free radical issue. You have to quench those free radicals and then support the tissues to repair the damage that has been done.

One thing we haven't mentioned yet, of course, is hepatic detoxification pathways. Does that sound familiar? Sounds like the 4R program to me! As I began to understand what you were saying (and it took a year and a half of listening to the *PMU* and *FMU* tapes over and over), I finally said, "oh, a common pathway." If you understand what we're talking about today, it is finally a common pathway for everything from allergic rhinitis to AIDS. It is a very exciting time in my life, and I think a very exciting time for you, too, because look at how what you've pioneered is now moving into the allopathic consciousness.

BIBLIOGRAPHY

1. Christen S, Woodall, AA, Shigenaga, Ames B, et al. Gamma-tocopherol traps mutagenic electrophiles such as NO and complements alpha tocopherol: Physiological implications. *Proc Natl Acad Sci*. 1997;94:3217-3222.
2. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. *N Engl J Med*. 1997;337(9):581-588.
3. Connor WE, Connor SL. Should a low-fat, high-carbohydrate diet be recommended for everyone? *N Engl J Med*. 1997;337(8):562-563.
4. Curfman GD. Diet pills redux. *N Engl J Med*. 1997;337(9):629-630.
5. Diaz MN, Frei B, Vita JA, Keaney JF. Antioxidants and atherosclerotic heart disease. *N Engl J Med*. 1997;337(6):408-414.
6. Dieterich W, Ehnis T, Bauer M, et al. Identification of tissue transglutaminase as the autoantigen of celiac disease. *Nature Med*. 1997;3(7):797-801.
7. Featherstone C. Soothing the troubled gut with trefoil factors. *Lancet*. 1997;349:706.
8. Fleischmann R, Demharter R, Barnert J, Füger K, Wienbeck M, Busch R. Eradication of *Helicobacter pylori* in peptic ulcer disease with amoxicillin, 2.0g, and omeprazole, 80 or 120mg: a prospective randomized trial. *Eur J Gastroenterol Hepatol*. 1997;9(6):593-598.
9. Garleb KA, Snook JT, Marcon MJ, Wolf BW, Johnson WA. Effect of fructooligosaccharide containing enteral formulas on subjective tolerance factors, serum chemistry profiles, and faecal bifidobacteria in healthy adult male subjects. *Microbial Ecol Health Dis*. 1996;9:279-285.
10. Johnston SC, Pelletier LL. Enhanced hepatotoxicity of acetaminophen in the alcoholic patient. *Medicine*. 1997;76(3):185-191.
11. Katan MB, Grundy SM, Willett WC. Beyond low-fat diets. *N Engl J Med*. 1997;337(8):563-567.
12. Katoh J, Tsuchiya K, Sato W, Nakajima M, Lida Y. Cimetidine and immunoreactivity. *Lancet*. 1996;348(9024):404-405.
13. Kernès S, Bogdanova A, Kraehenbuhl JP, Pringault E. Conversion by Peyer's patch lymphocytes of human enterocytes into M cells that transport bacteria. *Science*. 1997;277:949-952.
14. Kritchevsky D, Tepper SA, Klurfeld DM. Dietary protein and atherosclerosis. *JAOCS*. 1987;64(8):1167-1171.
15. Madara JL. The chameleon within: improving antigen delivery. *Science*. 1997;277:910-911.
16. Mark EJ, Patalas ED, Chang HT, Evans RJ, Kessler SC. Fatal pulmonary hypertension associated with short-term use of fenfluramine and phentermine. *N Engl J Med*. 1997;337(9):602-606.
17. Marsh MN. Transglutaminase, gluten and celiac disease: food for thought. *Nature Med*. 1997;3(7):725-726.
18. Martek's oils improve growth of preterm infants; also reduce nervousness and irritability. *Individual, Inc*. 1997.
19. Public Health. G1. 1997;18:135-161.
20. Rapola JM, Virtamo J, Ripatti S, et al. Randomised trial of *a*-tocopherol and *B*-carotene supplements on incidence of major coronary events in men with previous myocardial infarction. *Lancet*. 1997;349(9067):1715-1720.
21. Rose JB. Environmental ecology of *cryptosporidium* and public health implications. *Ann Rev*.
22. Ryan AJ, Chang RT, Gisolfi CV. Gastrointestinal permeability following aspirin intake and prolonged running. *Med Sci Sports Exercise*. 1996;28(6):698-705.
23. Senior K. How can components of common foods affect cancer risk? *Mol Med Today*. 1997(March):103-107.

24. Setchell KD, Zimmer-Nechemias L, Cai J, Heubi JE. Exposure of infants to phyto-oestrogens from soy-based infant formula. *Lancet*. 1997;350:23-27.
25. Shgur U, Tamm E, Torm S, Lutsar I, Salminen S, Midtvedt T. Effect of bacterial infection and administration of a probiotic on faecal short-chain fatty acids. *Microbial Ecol Health Dis*. 1996;9:271-277.
26. Sivam GP, Lampe JW, Ulness B, Swanzy SR, Potter JD. *Helicobacter pylori* -- In vitro susceptibility to garlic (*Allium sativum*) extract. *Nutr Cancer*. 1997;27(2):118-121.
27. Stephens N. Anti-oxidant therapy for ischaemic heart disease: where do we stand? *Lancet*. 1997;349(9067):1710-1711.
28. Sturgill MG, Lambert GH. Xenobiotic-induced hepatotoxicity: mechanisms of liver injury and methods of monitoring hepatic function. *Clin Chem*. 1997;43(8B):1512-1526.
29. Thurman RG, Bradford BU, Limuro Y, et al. Role of Kupffer cells, endotoxin and free radicals in hepatotoxicity due to prolonged alcohol consumption: studies in female and male rats. *J Nutr*. 1997;127(5S):903S-906S.

p>